Cited by 441Cancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisFerroptosis and cancer prognosis

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Open access

Valero, Cristina, Lee, Mark, Hoen, Douglas, Weiss, Kate, Kelly, Daniel W., Adusumilli, Prasad S., Paik, Paul K., Plitas, George, Ladanyi, Marc, Postow, Michael A., Ariyan, Charlotte E., Shoushtari, Alexander N., Balachandran, Vinod P., Hakimi, A. Ari, Crago, Aimee M., Long Roche, Kara C., Smith, J. Joshua, Ganly, Ian, Wong, Richard J., Patel, Snehal G., Shah, Jatin P., Lee, Nancy Y., Riaz, Nadeem, Wang, Jingming, Zehir, Ahmet, Berger, Michael F., Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G. T.·2021·Nature Communications

DOI 10.1038/s41467-021-20935-9PMC PMC7851155

Open this paper in CoChat — free account Open PDF

Abstract

Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P < 0.001) in the NLR low/TMB high group compared to the NLR high/TMB low group. NLR is a suitable candidate for a cost-effective and widely accessible biomarker, and can be combined with TMB for additional predictive capacity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41467-021-20935-9

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Pan-cancer outcomes based on neutrophil-to-lymphocyte ratio (NLR). a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level based on high vs. low NLR. The cutoff was the top 20th percentile within each cancer type. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central

Fig. 2 Outcomes based on neutrophil-to-lymphocyte ratio (NLR) stratified by cancer type. Forest plots showing hazard ratios (HRs) with 95% CIs for a overall survival and b progression-free survival across cancer types, comparing top 20th NLR percentile within each cancer type to bottom 80th. HRs were calculated with Cox proportional hazard regression. Abreviations: OS, overall survival; Haz. Ratio, hazard ratio; CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PFS, progression-free survival.CC BY · PubMed Central

Fig. 3 Pan-cancer outcomes according to a combined neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB) categorization. a Overall survival, b progression-free survival, c response, and d clinical benefit at a pan-cancer level. Patients were classified into four categories based on NLR low/high and TMB low/high, using median within cancer type as cutoff for both variables. P-values are according to log-rank test for a and b, and Pearson’s χ2-test for c and d.CC BY · PubMed Central

Fig. 4 Outcomes across quartile-based categories of neutrophil-to-lymphocyte ratio (NLR) and tumor mutational burden (TMB). Heat maps of hazard ratios (HRs) for a overall survival and b progression-free survival, and heat maps of odds ratios (ORs) for c response and d clinical benefit based on 16 within cancer type quartile-based categories of NLR and TMB. HRs were calculated with Cox proportional hazard regression. ORs were calculated with logistic regression.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Self-citation
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Self-citation
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citation

Show all 57 references

Research works printed but not linked: 1

Amin, M. B. et al. AJCC Cancer Staging Manual (Springer, 2017).

Sorted by citations

Items 201–300 of 441

Pretreatment nutritional indices are associated with survival and T-cell exhaustion in recurrent or metastatic oral squamous cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective cohort study
Ooyama, T., Hirayama, M., Seki, Y., Iwamoto, A., Yoshida, R., & Nakayama, H. (2025) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2025.01.010 · Cited by 8
Unlocking IL-18: A hidden key in cancer immunity
Manesh, S. S., Debeaud, M., & Vouret‐Craviari, V. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101997 · Cited by 8
High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors
Calo, C. A., Barrington, D. A. M., Brown, M. D., Gonzalez, L., Baek, J., Huffman, A., Benedict, J., Backes, F. J., Chambers, L., Cohn, D. E., et al. (2022) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2022.101040 · Cited by 8
Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer
Zeng, Z., Liu, Z., Li, J., Sun, J., Ma, M., Ye, X., Yu, J., & Kang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1065716 · Cited by 8
Identification of heterogeneous subtypes and a prognostic model for gliomas based on mitochondrial dysfunction and oxidative stress-related genes
Li, J., Wang, S., Chi, X., He, Q., Tao, C., Ding, Y., Jia, W., Zhao, J., & Wang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183475 · Cited by 8
Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE
Qu, S., Wu, D., & Hu, Z. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231206704 · Cited by 8
The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study
Samejima, H., Kojima, K., Fujiwara, A., Tokunaga, T., Okishio, K., & Yoon, H. (2023) · BMC Cancer · doi:10.1186/s12885-023-11604-9 · Cited by 8
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
Yang, Z., Zuo, Q., Liu, R., Wu, H., Li, X., Jia, J., & Xiang, Z. (2023) · BMC Cancer · doi:10.1186/s12885-023-11608-5 · Cited by 8
Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy
Zhen, S., Wang, W., Qin, G., Lu, T., Li, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1316778 · Cited by 11
THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data
Wang, Y., Guan, Y., Lai, X., Liu, Y., Chang, Z., Wang, X., Wang, Q., Liu, J., Zhao, J., Yang, S., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae648 · Cited by 8
Self-citation
Finding novel prognostic factors in metastatic renal cell carcinoma: what does peripheral blood tell us?
Marandino, L., on behalf of the EAU Young Academic Urologists (YAU) Renal Cancer Working Group, Campi, R., Erdem, S., Bertolo, R. G., Marchioni, M., Ingels, A., Kara, Ö., Carbonara, U., Pecoraro, A., et al. (2022) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.22.04957-6 · Cited by 8
High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer
Xiao, D., Deng, Q., He, D., Huang, Y., Liang, W., Wang, F., & Yang, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s325443 · Cited by 8
Baseline (derived) neutrophil-lymphocyte ratio associated with survival in gastroesophageal junction or gastric cancer treated with ICIs
Yu, C., Jiang, H., Wang, L., Jiang, Z., & Jin, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1404695 · Cited by 7
Prognostic Significance of Neutrophil‐to‐Lymphocyte Ratio in Melanoma: A Systematic Review and Meta‐Analysis
Yang, Y., Fang, H., Cai, Z., & Xu, Q. (2025) · Journal of Surgical Oncology · doi:10.1002/jso.70039 · Cited by 9
Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma
Şahin, G., Acar, C., Yüksel, H. Ç., Tünbekici, S., Açar, F. P., Çelebi, G., & Karaca, B. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04024-7 · Cited by 7
Mechanistic roles of neutrophil heterogeneity in tumour pathogenesis
Lin, H., Liao, Y., Chen, Z., Chen, Y., Chen, Y., Wang, Y., & Chen, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1721090 · Cited by 7
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Garralda, E., Abbott, C. W., Calahorro, A., Mirallas, O., Pugh, J. L., Moreno-Cárdenas, A. B., Keough, K. C., Galvao, V., Alonso, G., Olano, A. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2312 · Cited by 7
Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors
Chen, S., Hu, Y., Cheng, H., Guo, S., Han, Y., & Li, K. (2026) · Biomarker Research · doi:10.1186/s40364-026-00892-5 · Cited by 7
Blood- and Imaging-Derived Biomarkers for Oncological Outcome Modelling in Oropharyngeal Cancer: Exploring the Low-Hanging Fruit
Volpe, S., Gaeta, A., Colombo, F., Zaffaroni, M., Mastroleo, F., Vincini, M. G., Pepa, M., Isaksson, L. J., Turturici, I., Marvaso, G., et al. (2023) · Cancers · doi:10.3390/cancers15072022 · Cited by 7
Complete tumor resection reverses neutrophilia-associated suppression of systemic anti-tumor immunity
Kaskas, A. M., Clavijo, P. E., Friedman, J., Craveiro, M., & Allen, C. T. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106705 · Cited by 7
Evaluation of Radiomics as a predictor of efficacy and the tumor immune microenvironment in anti-PD-1 mAb treated Recurrent/Metastatic HNSCC patients
Zandberg, D., Zenkin, Ş., Ak, M., Mamindla, P., Peddagangireddy, V., Hsieh, R., Anderson, J. L., Delgoffe, G. M., Menk, A., Skinner, H. D., et al. (2024) · Head and Neck · doi:10.1002/hed.27878 · Cited by 8
Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab
Mii, S., Kato, H., Takahara, T., Kojima, M., Kato, Y., Morise, Z., Horiguchi, A., & Suda, K. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03834-x · Cited by 9
Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors
Hamada, K., Tsunoda, T., & Yoshimura, K. (2022) · Life · doi:10.3390/life12081229 · Cited by 8
Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
Zhang, Z., Yang, L., Wang, D., Ruan, Y., Zhang, J., Zhao, L., Yang, L., & Lou, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231169981 · Cited by 7
Albumin-Bilirubin (ALBI) Score and Systemic Immune-Inflammation Indexes Used As Pretreatment Outcome Predictors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Robotic or Open Whipple Procedures: A Logistic Regression Analysis
Mejia, A., Vivian, E., Shah, J., & Gutierrez, J. C. B. (2023) · Cureus · doi:10.7759/cureus.50949 · Cited by 7
Self-citation
Prognostic value of circulating tumor cells combined with neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma
Chen, J., Guo, L., Wu, Z.-Y., He, K., Han, L., Yang, C., & Han, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i2.372 · Cited by 7
Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study
Du, J., Zhang, Q., Tian, L., Chen, Y., Tian, Y., Dempke, W. C. M., Arasanz, H., Soo, R. A., Zhou, Z., Meng, Q., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1826 · Cited by 6
Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial
Zhang, W., Gong, C., Huang, J., Liu, T., Sun, Y., Jiang, Z., Qu, W., Yang, L. F., Xin, Y., Zhao, F., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04237-3 · Cited by 8
Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
Pîrlog, C.-F., Cotan, H. T., Paroșanu, A. I., Slavu, C. O., Popa, A. M., Iaciu, C. I., Olaru, M., Oprița, A. V., Niță, I., & Niţipir, C. (2022) · Cureus · doi:10.7759/cureus.26843 · Cited by 6
Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
Wang, Y., Mathai, J., Alamgeer, M., Parakh, S., Paul, E. M., Mitchell, P. L. R., & Arulananda, S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100544 · Cited by 6
Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation
Hreich, S. J. D., Humbert, O., Pacé-Loscos, T., Schiappa, R., Juhel, T., Ilié, M., Ferrari, V., Benzaquen, J., Hofman, P. M., & Vouret‐Craviari, V. (2024) · Cancers · doi:10.3390/cancers16122226 · Cited by 6
The Predictive Value of NLR, PLR, LMR, NPAR and D-Dimer on the Efficacy and Prognosis of First-Line Immunotherapy for Extensive-Stage Small Cell Lung Cancer
Shen, Y., Wang, J., Hua, Q., & Dong, M. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s557312 · Cited by 6
Self-citation
From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy
Wijnen, S. C. M. A., Dimitriadis, P., Wessels, L. F. A., & Blank, C. U. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116711 · Cited by 5
Chemotherapy-induced activation of caspase-1 and IL-1α release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation
Wong, S. T. C., Hayashi, K., Subel, E. J., Huang, Y.-H., Gao, H., Garcia, H. E., Porter, S. J., Karabicici, M., Hoi, X. P., Alonzo, M. D., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71471-3 · Cited by 5
High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse
Matsumoto, H., Fukushima, T., Kobayashi, N., Higashino, Y., Muraoka, S., Ohtsu, Y., Hirata, M., Somekawa, K., Kaneko, A., Nagasawa, R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299760 · Cited by 5
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach
Sorich, M. J., Manning‐Bennett, A. T., Li, L. X., Shahnam, A., Kichenadasse, G., Karapetis, C. S., Abuhelwa, A. Y., McKinnon, R. A., Rowland, A., & Hopkins, A. M. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01124-2 · Cited by 5
A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients
Wang, M., Yue, X., Ding, Y., Cai, Z., Xiao, H., Huang, H., & He, J. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s495284 · Cited by 7
Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors
Aslan, V., Kılıç, A. C. K., Cennet, N. R., Yücel, T. A., İnci, B. K., Gürler, F., Özet, A., Özdemir, N., Kılıç, K., & Yazıcı, O. (2025) · Scientific Reports · doi:10.1038/s41598-025-00708-w · Cited by 5
Positron Emission Tomography–Computed Tomography Imaging, Genomic Profile, and Survival in Patients With Head and Neck Cancer Receiving Immunotherapy
Fitzgerald, C. W. R., Valero, C., Swartzwelder, C. E., & Morris, L. G. T. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.1763 · Cited by 5
Self-citation
Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
Zhao, X., Wu, X., Yu, H., Wang, H., Sun, S., Hu, Z., Liu, C., Zhang, J., Shao, Y. W., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1003581 · Cited by 5
Self-citation
Higher aorta dose increased n eutrophil‐to‐lymphocyte ratio resulting in poorer outcomes in stage II‐III non‐small cell lung cancer
Li, Y., Fan, X., Yu, Q., Zhai, H., Mi, J., Lu, R., Jiang, G., & Wu, K. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14778 · Cited by 5
Neutrophil‑to‑lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer
Tanioka, H., Okawaki, M., Yano, S., Yoshimitsu, T., Tokuda, K., Nyuya, A., Yamaguchi, Y., & Nagasaka, T. (2023) · Oncology Letters · doi:10.3892/ol.2023.13684 · Cited by 5
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study
Nakamoto, S., Shien, T., Itoh, M., Yamamoto, Y., Ohsumi, S., Yoshitomi, S., Hikino, H., Miyoshi, K., Notsu, A., Taira, N., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01230-x · Cited by 5
Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer
Li, X., Zhang, Y., Zhu, C., Xu, W., Hu, X., Martínez, D. A. S., Romero, J. L. A., Yan, M., Dai, Y., & Wang, H. (2024) · BMC Women s Health · doi:10.1186/s12905-023-02871-6 · Cited by 5
Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer
Ren, Y. R., Wang, Q., Xu, C., Guo, Q., Dai, R., Xu, X., Zhang, Y., Wu, M., Wu, X., & Tu, H. (2024) · Cancers · doi:10.3390/cancers16030513 · Cited by 5
Increased Apolipoprotein A1 Expression Correlates with Tumor-Associated Neutrophils and T Lymphocytes in Upper Tract Urothelial Carcinoma
Chang, C., Chang, C.-B., Chen, C.-J., Tung, C., Hung, C., Lai, W., Shen, C., Tsai, C., Lai, Y.-Y., Lee, M., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030139 · Cited by 5
Self-citation
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)
Akyıldız, A., Güven, D. C., Köksal, B., Karaoğlan, B. B., Kivrak, D., İsmayılov, R., Aslan, F., Sütçüoğlu, O., Yazıcı, O., Kadıoğlu, A., et al. (2024) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-024-08744-4 · Cited by 5
Prognostic value of sarcopenia and inflammatory indices synergy in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy
Xiao, L., Liu, Y., Zhang, X., Nie, X., Bai, H., Lyu, J., & Li, T. (2024) · BMC Cancer · doi:10.1186/s12885-024-12602-1 · Cited by 5
Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials
Zhou, J., Wong, A. H., Wang, H., Jin, S., Tan, F., Chen, Y.-Z., He, S., Shen, G., Frey, B., Fietkau, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961926 · Cited by 5
Radiomics-based prediction of response to immune checkpoint inhibitor treatment for solid cancers using computed tomography: a real-world study of two centers
Yu, Y., Bai, Y.-P., Zheng, P., Wang, N., Deng, X., Ma, H.-H., Yu, R., Ma, C., Liu, P., Xie, Y., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10344-6 · Cited by 5
Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse
Wang, H., Liu, L., Yan, J., Ma, W., Du, Y., & Zhang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1097816 · Cited by 5
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
Fidalgo, J. A. P., Guerra, E. M., García, Y. G., Iglesias, M., Hernández‐Sosa, M., Estévez-García, P., Manso, L., Santaballa, A., Oaknin, A., Redondo, A., et al. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004028 · Cited by 5
First-line immunotherapy in non-small cell lung cancer: how to select and where to go
Mogavero, A., Cantale, O., Mollica, V., Anpalakhan, S., Addeo, A., Mountzios, G., Friedlaender, A., Kanesvaran, R., Novello, S., & Banna, G. L. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2302356 · Cited by 5
Neutrophil-to-lymphocyte Ratio Is a Predictive Marker for Anti- MDA5 Positive DermatomyositisPreprint
Liu, T., Li, W., Zhang, Z., Jiang, T., Fei, Y., Huang, J., & Xie, Q. (2022) · Research Square · doi:10.21203/rs.3.rs-1605447/v1 · Cited by 5
A machine learning model utilizing CT radiomics features and peripheral blood inflammatory markers predicts the prognosis of patients with unresectable esophageal squamous cell carcinoma undergoing PD-1 inhibitor combined with concurrent chemoradiotherapy
Liu, X., Gao, F., Wu, S., Wang, H., Dang, W., Sun, M., Zhang, Z., Li, M., Cai, Z., Li, W., et al. (2025) · Journal of Cancer · doi:10.7150/jca.105171 · Cited by 4
Dual-Pronged Lipid Nanocarriers Promote Immunotherapy for TNBC by Inducing Immunogenic Cell Death and Activating Lymphoid Immune Cells
Ye, J., Wang, S., Wu, S., Li, R., Li, X., Chen, S., Wang, Y., Wang, L., Qin, C., Wang, H., et al. (2026) · Research · doi:10.34133/research.1139 · Cited by 4
Self-citation
Delta-radiomics features combined with haematological index predict pathological complete response after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer
Xiong, D., Li, J., Li, L., Xu, F., Hu, T., Zhu, H., Xu, X., Sun, Y., & Yuan, S. (2025) · Clinical Radiology · doi:10.1016/j.crad.2025.106906 · Cited by 4
Super-high tumor mutational burden predicts complete remission following immunotherapy: from Peto’s paradox to druggable cancer hallmark
Zheng, M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010486 · Cited by 5
Leveraging readily available clinical data with machine learning to predict first-line immunotherapy outcomes in non-small cell lung cancer
Liu, F., Huang, R. S., Wang, Q., Wang, R., Lu, J., Zhang, Y., Ma, X., Liu, X., Kong, X., Li, P., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115259 · Cited by 4
Predictors of distant metastases in sinonasal and skull base cancer patients treated with surgery
Valero, C., Adilbay, D., Fitzgerald, C. W. R., Yuan, A., S, X. M., Gupta, P., Wong, R. J., Shah, J. P., Patel, S. G., Cohen, M. A., et al. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105575 · Cited by 4
Self-citation
Biomarkers for immune checkpoint inhibitors in solid tumors
Kapoor, V., & Kelly, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02942-4 · Cited by 4
Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer
Zhang, C., Huo, Y., Shang, X., Zhang, T., Tang, N., & Wang, H. (2024) · Respiratory Research · doi:10.1186/s12931-024-02885-0 · Cited by 4
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Thunold, S., Hernes, E., Farooqi, S. J., Öjlert, Å. K., Francis, R. J., Nowak, A. K., Szejniuk, W. M., Nielsen, S. S., Cedrés, S., Simó, M., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06853-0 · Cited by 4
Prediction of Neoadjuvant Chemoradiotherapy Sensitivity in Patients With Esophageal Squamous Cell Carcinoma Using CT-Based Radiomics Combined With Clinical Features
Li, X., Dong, J., Li, B., Aimei, O., Sun, Y., Wu, X., Liu, W., Li, R., Li, Z., & Yu, Y. (2024) · Dose-Response · doi:10.1177/15593258241301525 · Cited by 4
Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis
Zhang, Z., Zhao, W., Lv, C., Wu, Z., Liu, W., Chang, X., Yu, Y., Xiao, Z., He, Y., & Zhang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456150 · Cited by 4
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials
Zoghbi, M., Patel, B., Dugage, M. R., Mezquita, L., Bahleda, R., Dufresne, A., Brahmi, M., Ray-Coquard, I. L., Pautier, P., Blay, J., et al. (2024) · Cancers · doi:10.3390/cancers16234053 · Cited by 4
Non‐Genetic Biomarkers in Merkel Cell Carcinoma: Prognostic Implications and Predictive Utility for Response to Anti‐ PD ‐(L)1 Immune Checkpoint Inhibitors
Drum, D. L., Jallorina, A. G., Wan, L. S., Chang, V. T.-S., & Lee-Wong, M. F. (2025) · Experimental Dermatology · doi:10.1111/exd.70030 · Cited by 4
Overview on biomarkers for immune oncology drugs
Имянитов, Е. Н., Преображенская, Е. В., & Mitiushkina, N. V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002298 · Cited by 5
Negative Effect of Intravenous Antibiotics on Survival in Patients with Triple-Negative Breast Cancer
Lukac, S., Fink, V., Dayan, D., Rack, B. K., Janni, W., Látó, K., Veselinovic, K., Heublein, S., Friedl, T. W. P., & Leinert, E. (2025) · Cancers · doi:10.3390/cancers17091498 · Cited by 4
Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
Faraji, F., Cohen, E. E. W., & Guo, T. W. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-1 · Cited by 4
Considerations for the clinical development of immuno-oncology agents in cancer
Pandiella, A., Calvo, E., Moreno, V., Amir, E., Templeton, A. J., & Ocaña, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229575 · Cited by 4
Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity
Motofei, I. G. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2020243 · Cited by 5
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients
Hirasawa, Y., Kubota, Y., Mura, E., Suzuki, R., Tsurui, T., Iriguchi, N., Ishiguro, T., Ohkuma, R., Shimokawa, M., Ariizumi, H., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1449941 · Cited by 3
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
Deng, J., Gao, M., Fan, X., Yan, H.-H., Luo, W., Yang, M., Yang, X., Chen, Z., Xu, C., & Zhou, Q. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03984-7 · Cited by 3
Machine learning-based predictive model for immune checkpoint inhibitors response in gastrointestinal cancers
Lv, Y., Wang, Q., Xu, H., Dai, J., & Wei, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1631011 · Cited by 3
Optimizing Surface Functionalization for Aptameric Graphene Nanosensors in Undiluted Physiological Media
Dai, W., Wang, Z., Yu, S., Wen, K., Yang, Y., & Lin, Q. (2026) · Sensors · doi:10.3390/s26020744 · Cited by 3
Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer
Fang, J., Yu, Y., Sun, Y., Chen, X., Yan, C., Sun, Q., & Jin, G. (2026) · BMC Cancer · doi:10.1186/s12885-026-15623-0 · Cited by 3
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study
Labidi, S., Meti, N., Barua, R., Li, M., Riromar, J., Jiang, D., Fallah‐Rad, N., Sridhar, S. S., Rincon, S. V. D., Pezo, R. C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081480 · Cited by 3
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Študentová, H., Holá, K., Melichar, B., & Spisarová, M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2341734 · Cited by 4
Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study
Hulst, L. A., Cappuyns, S., Peeters, F., Vulsteke, F., Herpe, F. V., Cutsem, E. V., & Dekervel, J. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.06.004 · Cited by 3
Radiomics nomogram combined with clinical factors for predicting pathological complete response in resectable esophageal squamous cell carcinoma
Lu, Z., Li, Y., Hu, W., Cao, Y., Lv, X., Jia, X., Shen, S., Zhao, J., & Xu, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347650 · Cited by 3
Remnant cholesterol and systemic inflammation as synergistic predictors of cancer risk: A 16‐year prospective cohort study
Xu, H.-X., Liu, P.-P., Chen, S., Wang, G., Wu, S., & Zhang, X.-M. (2025) · Cancer · doi:10.1002/cncr.70096 · Cited by 6
Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
Ji, X., Zhou, B., Ding, W., Wang, J., Jiang, W., Li, Y., Hu, J., & Sun, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925043 · Cited by 3
Self-citation
Clinical relevance of neutrophil/lymphocyte ratio combined with APACHEII for prognosis of severe heatstroke
Tang, Y., Gu, T., Wei, D., Yuan, D., & Liu, F. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20346 · Cited by 3
Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy
Shi, Z., Zhu, S., Jin, Y., Liang, Q., Zhou, M., Zhou, Z., Zhang, J., Liu, B., & Shen, J. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s452424 · Cited by 3
Heterogeneous characterization of neutrophilic cells in head and neck cancers
Fay, M., Clavijo, P. E., & Allen, C. T. (2024) · Head & Neck · doi:10.1002/hed.27774 · Cited by 3
TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors
Lai, X., Wang, S., Zhang, X., Zhu, X., Liu, Y., Chang, Z., Wang, X., Shao, Y. W., Wang, J., & Wang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1514295 · Cited by 3
Self-citation
Area Deprivation and Clinical Biomarkers of Inflammation in Cancer Survivors of the National Institutes of Health All of Us Research Program
Byrne, C. A., Oddo, V. M., Karayeva, E., Kopetsky, G., & Kim, S. J. (2025) · Cancer Medicine · doi:10.1002/cam4.70784 · Cited by 3
Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia
Alshamsan, B., Aseafan, M., Badran, A. A., Shaheen, A., Elshenawy, M. A., Bazarbashi, S. N., & Aljubran, A. H. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2613 · Cited by 3
Circulating Cell-in-Cell Tumor Cells with Neutrophil Signature are Hematogenous Metastasis-Initiating CellsPreprint
Chen, X., Yuan, X., Chen, Y., Cui, X., Cao, N., Yi, M., Xu, H., Yao, N., Yu, U., Chen, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4781922 · Cited by 2
Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
Oshima, M., Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Nakayama, A., Nagamoto, S., Nakayama, T., Izumi, K., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100106 · Cited by 2
Unveiling the power of Treg.Sig: a novel machine-learning derived signature for predicting ICI response in melanoma
Fan, Y., Yang, J., Yang, X., Xie, Y., Li, H., Yang, S., Sun, G., Gé, G., Ding, X. L., Lai, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1508638 · Cited by 2
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study
Nie, S., Song, S., Xu, Q., Dai, X., Liu, A., Sun, M., Cong, L., Liang, J., Liu, Z., Lv, J., et al. (2025) · Gastric Cancer · doi:10.1007/s10120-025-01655-1 · Cited by 2
Effective dose to immune cells combined with platelet-to-lymphocyte ratio predicts lymphopenia and prognosis in unresectable locally advanced non-small cell lung cancer
Yang, H., Ma, J., Tian, C., Bao, S., Zhang, J., Wang, F., Xu, Y., Yu, J., & Chen, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657972 · Cited by 2
Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors
Li, J., Wang, Y., Pei, J., Wang, M., Wang, D., Guo, R., & Qiu, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-02862-z · Cited by 2
A cytokine-based serum proteomic score is a prognostic biomarker for immunotherapy in head and neck cancer
Saif, S. I., Sehgal, K., Zhang, Z., Butler, R. A., Wiencke, J. K., Molinaro, A. M., Miller, J., Stolrow, H. G., Shirai, K., Salas, L. A., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04271-1 · Cited by 2
A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell lung cancer
Mai, V. H., Prasanpanich, M., Zungsontiporn, N., Korphaisarn, K., Sitthideatphaiboon, P., Aporntewan, C., Chantranuwat, P., Hirankarn, N., & Vinayanuwattikun, C. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70076 · Cited by 2
Development and analysis of a nomogram for predicting pathological response to neoadjuvant immunochemotherapy in locally advanced gastric cancer
Yu, H., Pu, Y., Wang, L., & Li, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1737833 · Cited by 2
Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype
Gantzer, J., Lu, X., Weingertner, N., Fattori, A., Chenard, M., Plassard, D., Amri, A. E., Sauleau, E., Gangi, A., Kurtz, J., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116905 · Cited by 2
Prognostic Value of Combined Neutrophil-to-Lymphocyte Ratio and Imaging Tumor Capsule in Solitary Hepatocellular Carcinoma Patients after Narrow-Margin Hepatectomy
Chen, D., Mao, P.-J., Sun, C., Fan, X., Zhu, Q., Chen, Z., He, Z., Lou, Y., & Sun, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020351 · Cited by 2

Authors: Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., Ariyan, C. E., Shoushtari, A. N., Balachandran, V. P., Hakimi, A. A., Crago, A. M., Long Roche, K. C., Smith, J. J., Ganly, I., Wong, R. J., Patel, S. G., Shah, J. P., Lee, N. Y., Riaz, N., Wang, J., Zehir, A., Berger, M. F., Chan, T. A., Seshan, V. E., & Morris, L. G. T.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Chan, Timothy A.
Seshan, Venkatraman E.
Morris, Luc G. T.
ORCID: Valero, Cristina
Lee, Mark
Weiss, Kate
Kelly, Daniel W.
Adusumilli, Prasad S.
Paik, Paul K.
Plitas, George
Ladanyi, Marc
Postow, Michael A.
Ariyan, Charlotte E.
Shoushtari, Alexander N.
Balachandran, Vinod P.
Hakimi, A. Ari
Crago, Aimee M.
Smith, J. Joshua
Ganly, Ian
Wong, Richard J.
Patel, Snehal G.
Shah, Jatin P.
Lee, Nancy Y.
Riaz, Nadeem
Wang, Jingming
Zehir, Ahmet
Berger, Michael F.
Chan, Timothy A.
Seshan, Venkatraman E.
Morris, Luc G. T.
Venue: Nature Communications
Publisher: Springer Science and Business Media LLC
Published: 2021-02-01
Volume: 12
Issue: 1
Pages: 729-729
ISSN: 2041-1723 (ISSN-L)
DOI: 10.1038/s41467-021-20935-9
PMC: PMC7851155
OpenAlex: W3127371144
Cited by: 441
References: 57
Citations by year: 2026: 53 · 2025: 74 · 2024: 116 · 2023: 92 · 2022: 80 · 2021: 26
FWCI: 28.60
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Nature Communications (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Fundación Alfonso Martín Escudero (N/A)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA205426, R35 CA232097)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: immune checkpoint inhibitors, neutrophil-to-lymphocyte ratio, tumor mutational burden, predictive biomarkers, tumor response, overall survival, progression-free survival, cancer immunotherapy, prognostic factors
MeSH terms: Progression-Free Survival, Immune Checkpoint Inhibitors, Aged, Female, Follow-Up Studies, Humans, Lymphocytes, Male, Middle Aged, Neoplasms, Neutrophils, Predictive Value of Tests, Retrospective Studies, Lymphocyte Count, Drug Resistance, Neoplasm, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks